Literature DB >> 7369403

Schizophrenia: affect and outcome.

T E Gift, J S Strauss, R F Kokes, D W Harder, B A Ritzler.   

Abstract

Considerable data suggest that schizophrenic patients with affective symptoms have a more favorable outcome than other schizophrenic patients. This may indicate that such patients are more validly regarded as having either an affective disorder or a schizoaffective psychosis. Studies of this issue have suffered from significant methodologic problems, including inappropriate sampling, unsystematic collection of symptom data, unreliable diagnostic procedures, and restricted outcome assessment. The present study, designed to surmount these methodologic difficulties, indicates that while levels of psychotic symptoms in schizophrenic patients correlate with poor outcome, affective symptoms have little prognostic power.

Entities:  

Mesh:

Year:  1980        PMID: 7369403     DOI: 10.1176/ajp.137.5.580

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  3 in total

1.  Clinical correlates of readmission in a schizophrenic cohort.

Authors:  T J Craig; S P Lin; M H el-Defrawi; A B Goodman
Journal:  Psychiatr Q       Date:  1985

2.  Prognostic Value of Affective Symptoms in First-Admission Psychotic Patients.

Authors:  Marta Arrasate; Itxaso González-Ortega; Adriana García-Alocén; Susana Alberich; Iñaki Zorrilla; Ana González-Pinto
Journal:  Int J Mol Sci       Date:  2016-06-30       Impact factor: 5.923

3.  Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study.

Authors:  Konstantinos N Fountoulakis; Elena Dragioti; Antonis T Theofilidis; Tobias Wikilund; Xenofon Atmatzidis; Ioannis Nimatoudis; Erik Thys; Martien Wampers; Luchezar Hranov; Trayana Hristova; Daniil Aptalidis; Roumen Milev; Felicia Iftene; Filip Spaniel; Pavel Knytl; Petra Furstova; Tiina From; Henry Karlsson; Maija Walta; Raimo K R Salokangas; Jean-Michel Azorin; Justine Bouniard; Julie Montant; Georg Juckel; Ida S Haussleiter; Athanasios Douzenis; Ioannis Michopoulos; Panagiotis Ferentinos; Nikolaos Smyrnis; Leonidas Mantonakis; Zsófia Nemes; Xenia Gonda; Dora Vajda; Anita Juhasz; Amresh Shrivastava; John Waddington; Maurizio Pompili; Anna Comparelli; Valentina Corigliano; Elmars Rancans; Alvydas Navickas; Jan Hilbig; Laurynas Bukelskis; Lidija Injac Stevovic; Sanja Vodopic; Oluyomi Esan; Oluremi Oladele; Christopher Osunbote; Janusz Κ Rybakowski; Pawel Wojciak; Klaudia Domowicz; Maria Luisa Figueira; Ludgero Linhares; Joana Crawford; Anca-Livia Panfil; Daria Smirnova; Olga Izmailova; Dusica Lecic-Tosevski; Henk Temmingh; Fleur Howells; Julio Bobes; Maria Paz Garcia-Portilla; Leticia García-Alvarez; Gamze Erzin; Hasan Karadağ; Avinash De Sousa; Anuja Bendre; Cyril Hoschl; Cristina Bredicean; Ion Papava; Olivera Vukovic; Bojana Pejuskovic; Vincent Russell; Loukas Athanasiadis; Anastasia Konsta; Dan Stein; Michael Berk; Olivia Dean; Rajiv Tandon; Siegfried Kasper; Marc De Hert
Journal:  Int J Neuropsychopharmacol       Date:  2019-11-01       Impact factor: 5.176

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.